Status:

COMPLETED

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

Lead Sponsor:

Takeda

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules. During the study, participants will receive one infusion of TAK-881 under the skin...

Eligibility Criteria

Inclusion

  • Men and Women between 18 and 50 years can participate.
  • Must be a non-smoker, with no use of nicotine or tobacco products for at least 3 months prior to the first dosing.
  • Must have Body Mass Index (BMI) between 18.0 and 30.0 kilograms per square meter (kg/m\^2).
  • Must be medically healthy.
  • Must follow protocol-specified contraception guidance.

Exclusion

  • Any current or past medical history of blood/clotting disorder, liver, lung, heart, kidney, immune, skin, or brain or psychiatric condition.
  • History of alcohol or drug abuse within 2 years before dosing.
  • History or presence of hypersensitivity or severe allergic reactions to blood or blood components.
  • History or presence of thrombotic/thromboembolic events, or venous thrombosis.
  • Pregnant or breastfeeding.
  • Unable to refrain from taking prescription and non-prescription medications, herbal remedies, homeopathic preparations, or vitamin supplements.
  • Recently donated blood or blood products.
  • Participated in another clinical trial involving immunoglobulin products within 12 months of screening.
  • Has taken biologic agents within 12 weeks of screening.
  • Has used an investigational product within 30 days or 5 half-lives, whichever is longer, prior to screening.
  • Has received any vaccine (including live attenuated vaccines and coronavirus disease 2019 \[COVID-19\] vaccines) during the last 30 days before dosing.

Key Trial Info

Start Date :

April 22 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 22 2025

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT06935266

Start Date

April 22 2025

End Date

September 22 2025

Last Update

November 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Celerion

Tempe, Arizona, United States, 85283

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults | DecenTrialz